J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says

Biopharmaceutical companies can't talk business strategy with investors for long these days without addressing the issue of US drug pricing and healthcare reform. That was the case during Johnson & Johnson’s commercial overview presentation Sept. 13, where Vice Chairman Joaquin Duato assured investors the diversified pharma is well positioned to absorb changes, whatever shape they take.

J&J executives stressed that the company derives all of its growth from volume, not from price increases. Duato boasted of a compound annual growth rate (CAGR) of 8.6% from 2010 to 2017 for J&J, double the 4